Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.

Clozapine is the prototype atypical antipsychotic drug, producing little or no extrapyramidal side effects, while improving negative symptoms of psychosis. Clozapine's high affinity for serotonin receptors has been hypothesized to confer the unique antipsychotic properties of this drug. Recently, we demonstrated that both typical and atypical antipsychotic drugs are inverse agonists at constitutively active 5-hydroxytryptamine2A (5-HT(2A)) receptors. To determine whether inverse agonist activity at 5-HT(2C) receptors plays a role in antipsychotic efficacy, typical and atypical antipsychotic drugs were tested for inhibition of basal inositol phosphate production in mammalian cells expressing rat or human 5-HT(2C) receptors. Atypical antipsychotic drugs (sertindole, clozapine, olanzapine, ziprasidone, risperidone, zotepine, tiospirone, fluperlapine, tenilapine) displayed potent inverse agonist activity at rat and human 5-HT(2C) receptors. Typical antipsychotic drugs (chlorpromazine, loxapine, thioridazine, prochlorperazine, perphenazine, mesoridazine, trifluperidol, fluphenazine, spiperone, haloperidol, pimozide, penfluridol, thiothixene) were devoid of inverse agonist activity, with the exception of loxapine. We review the evidence that loxapine has unique properties characteristic of both atypical and typical antipsychotic drugs. Several typical antipsychotic drugs (chlorpromazine, thioridazine, spiperone, thiothixene) displayed neutral antagonist activity by reversing clozapine inverse agonism. These data suggest that 5-HT(2C) inverse agonist activity is associated with atypical antipsychotic drugs with moderate to high affinity for 5-HT(2C) receptors, and imply that effects of atypical antipsychotic drugs on the 5-HT(2C) receptor may play a role in their unique clinical properties. These data also imply that dysfunction of brain 5-HT(2C) receptor systems may be one of the factors involved in the etiology of psychosis.

• Publication year

  2000

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2000-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/s0022-3565(24)38891-3PMID 10991983
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Mutation-induced Activated State of the ,&-Adrenergic Receptor EXTENDING THE TERNARY COMPLEX MODEL*

  2001cited by this paper
• Does loxapine have "atypical" properties? Clinical evidence.

  1999cited by this paper
• Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine?

  1999cited by this paper
• SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system.

  1999influential reference
• RNA Editing of the Human Serotonin 5-Hydroxytryptamine 2C Receptor Silences Constitutive Activity*

  1999cited by this paper
• Serotonin 5‐HT2C Receptor RNA Editing Alters Receptor Basal Activity

  1999cited by this paper
• The Role of Serotonin in Antipsychotic Drug Action

  1999cited by this paper
• Messenger RNA Editing of the Human Serotonin 5-HT2C Receptor

  1999cited by this paper
• Clozapine Preferentially Increases Dopamine Release in the Rhesus Monkey Prefrontal Cortex Compared with the Caudate Nucleus

  1999cited by this paper
• The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.

  1999influential reference
• Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens.

  1999cited by this paper
• Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors.

  1998cited by this paper
• Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs.

  1998influential reference
• The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis.

  1998cited by this paper
• Pharmacological Characterization of the Constitutively Activated State of the Serotonin 5‐HT2C Receptor

  1998cited by this paper
• 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites.

  1998cited by this paper
• Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation

  1998cited by this paper
• Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo.

  1998cited by this paper
• Serotonergic basis of antipsychotic drug effects in schizophrenia.

  1998cited by this paper
• 霊長類大脳皮質の5‐ヒドロキシトリプタミン2Aセロトニン受容体 錐体細胞先端樹状突起での幻覚剤及び抗精神病剤の作用部位

  1998cited by this paper
• Regulation of serotonin-2C receptor G-protein coupling by RNA editing

  1997influential reference
• Activating Mutations of the Serotonin 5‐HT2C Receptor

  1997cited by this paper
• Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selective for D4 Receptors

  1997cited by this paper
• Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground.

  1995cited by this paper
• Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness

  1994cited by this paper
• 5-HT1C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after chronic treatment with clozapine.

  1994cited by this paper
• Evidence that 5-HT2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety

  1994cited by this paper
• Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands.

  1994cited by this paper
• Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists.

  1994cited by this paper
• Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.

  1994influential reference
• Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas

  1993cited by this paper
• A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model.

  1993cited by this paper
• Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors.

  1992cited by this paper
• Phosphoinositide hydrolysis linked 5-HT2 receptors in fibroblasts from choroid plexus.

  1991cited by this paper
• Dopamine in schizophrenia: a review and reconceptualization.

  1991cited by this paper
• Acute Effects of Typical and Atypical Antipsychotic Drugs on the Release of Dopamine from Prefrontal Cortex, Nucleus Accumbens, and Striatum of the Rat: An In Vivo Microdialysis Study

  1990cited by this paper
• Distribution of serotonin 5‐HT1C receptor mRNA in adult rat brain

  1989cited by this paper
• Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

  1989influential reference
• Effector systems coupled to serotonin receptors in brain: serotonin stimulated phosphoinositide hydrolysis.

  1986cited by this paper
• Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs

  1976cited by this paper
• Antipsychotic drug doses and neuroleptic/dopamine receptors

  1976cited by this paper
• Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

  1976cited by this paper

• 5-Hydroxytryptamine receptors in GtoPdb v.2025.3

  2025cites this paper
• 5-Hydroxytryptamine receptors in GtoPdb v.2025.1

  2025cites this paper
• Molecular dynamics study of differential effects of serotonin-2A-receptor (5-HT2AR) modulators

  2025cites this paper
• G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders

  2023cites this paper
• Structure, function and drug discovery of GPCR signaling

  2023cites this paper
• 5-Hydroxytryptamine receptors in GtoPdb v.2023.1

  2023cites this paper
• The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children

  2021influential citation
• Exploring the kinetic selectivity of antipsychotics for dopamine D2 and 5-HT2A receptors: implications for the prevalence of EPS and receptor occupancy

  2021cites this paper
• Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates

  2021cites this paper
• 1,5‐Benzoxazepines as a unique and potent scaffold for activity drugs: A review

  2021cites this paper
• Constitutive activity of 5-HT receptors: Factual analysis.

  2020cites this paper
• International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function

  2020cites this paper
• 5-Hydroxytryptamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.

  2019cites this paper
• Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats

  2019cites this paper
• Decreased 5-HT 2 cR and GHSR 1 a interaction in antipsychotic drug-induced obesity 2 3

  2019cites this paper
• Association of Serotonin2c Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia

  2019cites this paper
• 5-HT2A Receptors in the Basal Ganglia

  2018cites this paper
• Behavioral Weight Loss Treatment in Antipsychotic Treated Youth.

  2018cites this paper
• Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.

  2018influential citation
• Decreased 5‐HT2cR and GHSR1a interaction in antipsychotic drug‐induced obesity

  2018cites this paper
• Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences

  2018cites this paper
• Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity

  2018cites this paper
• Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment

  2017cites this paper
• A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment

  2017cites this paper
• Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications

  2017cites this paper
• Prochlorperazine Increases KCC2 Function and Reduces Spasticity after Spinal Cord Injury

  2017cites this paper
• History Of The 5-HT 2 C Receptor : From The Choroid Plexus To Depression , Obesity And Addiction Treatment

  2017influential citation
• New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.

  2016cites this paper
• Behavioral Weight Loss Treatment for Youth Treated With Antipsychotic Medications

  2016cites this paper
• Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review

  2016cites this paper
• 5-HT2C receptors in psychiatric disorders: A review.

  2016cites this paper
• Loxapin — ein neues Antipsychotikum?

  2016influential citation
• New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.

  2016cites this paper
• Serotonin in antipsychotic drugs action.

  2015cites this paper
• Development of MEPS–UHPLC/PDA methodology for the quantification of clozapine, risperidone and their major active metabolites in human urine

  2015cites this paper
• Serotonin 5-HT2B receptor antagonism is fundamental for protecting PC12 cells exposed to hydrogen peroxide

  2015cites this paper
• Atypical antipsychotics and inverse agonism at 5-HT2 receptors.

  2015cites this paper
• The mechanisms for reducing olanzapineinduced weight gain/obesity by betahistine: clinical implications

  2014cites this paper
• Recovery of neuronal and network excitability after spinal cord injury and implications for spasticity

  2014cites this paper
• Combining antipsychotics; is this strategy useful?

  2014cites this paper
• Einfluss der Johanniskrautinhaltsstoffe Hyperforin, Hyperosid und Hypericin auf die laterale Mobilität und die Signaltransduktion von 5-HT 1A -Rezeptoren

  2014cites this paper
• Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists

  2014cites this paper
• Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology

  2013cites this paper
• Biotransformation of LASSBio-579 and pharmacological evaluation of p-hydroxylated metabolite a N-phenylpiperazine antipsychotic lead compound.

  2013cites this paper
• spasms after human spinal cord injury receptors facilitate muscle

  2013cites this paper
• Virtual Affinity Fingerprints for Target Fishing: A New Application of Drug Profile Matching

  2013cites this paper
• The neuropsychopharmacology of reversal learning

  2013cites this paper
• Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations

  2013cites this paper
• Acute antipsychotic treatments induce distinct c-Fos expression patterns in appetite-related neuronal structures of the rat brain.

  2013cites this paper
• Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications.

  2013cites this paper
• Metabolic effects of adjunctive aripiprazole in clozapine‐treated patients with schizophrenia

  2013cites this paper
• Constitutively active 5-HT2/α1 receptors facilitate muscle spasms after human spinal cord injury.

  2013cites this paper
• Drug safety and efficacy evaluation of sertindole for schizophrenia

  2012cites this paper
• Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.

  2012cites this paper
• 5-HT(2C) agonists as therapeutics for the treatment of schizophrenia.

  2012cites this paper
• Receptor targets for antidepressant therapy in bipolar disorder: an overview.

  2012cites this paper
• Virtual A ffi nity Fingerprints for Target Fishing : A New Application of 2 Drug Pro fi le Matching

  2012cites this paper
• Serotonergic mechanisms as targets for existing and novel antipsychotics.

  2012cites this paper
• Does steroid sulfatase deficiency influence postpartum psychosis risk?

  2012cites this paper
• 5‐HT2C and 5‐HT6 Receptor Targeted Emerging Approaches in Schizophrenia

  2012cites this paper
• Hippocampal serotonin depletion facilitates the enhancement of prepulse inhibition by risperidone: possible role of 5-HT(2C) receptors in the dorsal hippocampus.

  2011influential citation
• Inverse agonism and its therapeutic significance

  2011cites this paper
• Antiviral drugs against hepatitis C virus

  2011cites this paper
• Receptor mechanisms of antipsychotic drug action in bipolar disorder – focus on asenapine

  2011cites this paper
• The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment

  2011cites this paper
• The role of serotonin receptors in the action of atypical antipsychotic drugs.

  2011cites this paper
• Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia.

  2011cites this paper
• The serotonergic system in Parkinson's disease.

  2011cites this paper
• 5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

  2011cites this paper
• The 5-HT2C Receptor Subtype Controls Central Dopaminergic Systems: Evidence from Electrophysiological and Neurochemical Studies

  2011cites this paper
• The making of the 5-HT2C receptor

  2011cites this paper
• 5-HT2C Receptor Dimerization

  2011cites this paper
• Physiological and Pathophysiological Aspects of 5-HT2c Receptors in Basal Ganglia

  2011cites this paper
• The Constitutive Activity of 5-HT2C Receptors as an Additional Modality of Interaction of the Serotonergic System

  2011cites this paper
• The 5-HT2C Receptor as a Target for Schizophrenia

  2011cites this paper
• Atypical Antipsychotic-Induced Weight Gain

  2011cites this paper
• Differences between human wild-type and C23S variant 5-HT_2C receptors in inverse agonist-induced resensitization

  2011cites this paper
• Pharmacologic Rescue of Motivational Deficit in an Animal Model of the Negative Symptoms of

  2011cites this paper
• Novel structural insights for drug design of selective 5-HT(2C) inverse agonists from a ligand-biased receptor model.

  2010cites this paper
• The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen

  2010cites this paper
• Inverse agonism at serotonin and cannabinoid receptors.

  2010cites this paper
• Serotonin – Dopamine Interactions in Neuropsychiatric Disorders Depression

  2010cites this paper
• Role of Serotonin in Central Dopamine Dysfunction

  2010cites this paper
• A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle

  2010cites this paper
• A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects

  2010cites this paper
• Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.

  2010cites this paper
• Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.

  2009cites this paper
• Label-free optical biosensor: A tool for G protein-coupled receptors pharmacology profiling and inverse agonists identification

  2009cites this paper
• Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors

  2009cites this paper
• Serotonergic approaches in the development of novel antipsychotics.

  2008cites this paper
• Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.

  2008cites this paper
• Molecular biology of 5-HT receptors.

  2008cites this paper
• Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression.

  2008cites this paper
• Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies.

  2008influential citation
• Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications.

  2008cites this paper
• In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.

  2008cites this paper
• RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function.

  2008cites this paper
• Pharmacotherapy of insomnia

  2008cites this paper
• Isoflurane anesthesia inhibits clozapine- and risperidone-induced dopamine release and anesthesia-induced changes in dopamine metabolism was modified by fluoxetine in the rat striatum: an in vivo microdialysis study.

  2008cites this paper